Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease.

Akiko Takeuchi,T. Matsushita,Kenzo Kaji,Yoshinobu Okamoto,M. Yasui,M. Hirata,Naoto Oishi,A. Higashi,M. Seishima,Tomoya Asano,M. Fujimoto,M. Kuwana,K. Takehara,Y. Hamaguchi

DOI: https://doi.org/10.1016/j.jaut.2016.09.006

IF: 14.511

Journal of Autoimmunity

Abstract:

What problem does this paper attempt to address?

A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity

Manali Mukherjee,Martin Kolb

DOI: https://doi.org/10.1183/13993003.00653-2023

IF: 24.3

2023-05-20

European Respiratory Journal

Abstract:It is well established that several of the interstitial lung diseases (ILDs) are driven by autoimmunity, such as rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. These are therefore considered to be autoimmune diseases and frequently treated with immunosuppressive drugs. Idiopathic pulmonary fibrosis (IPF) is not viewed as an autoimmune disorder, but nevertheless, autoantibodies routinely studied in clinical practice are found in IPF and other types of idiopathic interstitial pneumonias. Serological autoreactivities, such as anti-cyclic citrullinated peptide antibody (anti-CCP), antinuclear antibody, rheumatoid factor (RF) and anti-neutrophil cytoplasmic antibody, have been reported in IPF [1] similar to patients with a connective tissue disease.

respiratory system
Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Sheng Li,Siting Zheng,Shunli Tang,Yunlei Pan,Shan Zhang,Hong Fang,Jianjun Qiao

DOI: https://doi.org/10.1007/s12016-019-08747-8

2019-01-01

Clinical Reviews in Allergy & Immunology

Abstract:Adult-onset Still’s disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology. AOSD is generally characterized by high spiking fever, arthralgia or arthritis, skin rash, leukocytosis, and hyperferritinemia. Traditionally, AOSD has been treated with non-steroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants. An increasing number of studies have shown that proinflammatory cytokines, such as interleukin-1β, -18, -6, and tumor necrosis factor-α, play key roles in AOSD and may serve as therapeutic targets. In the current review, we provided insights into the roles of these cytokines in the pathogenesis of AOSD and also provided a commentary on the clinical studies of biologic therapy against AOSD.
Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung disease

Sarah L Tansley,Fionnuala McMorrow,Caroline V Cotton,Huzaifa Adamali,Shaney L Barratt,Zoe E Betteridge,Janire Perurena-Prieto,Michael A Gibbons,Raman Kular,Aravinthan Loganathan,Janine A Lamb,Hui Lu,Robert P New,Diane Pratt,Pilar Rivera-Ortega,Ross Sayers,Matthew Steward,Lachlan Stranks,Edward Vital,Lisa G Spencer,Neil J McHugh,Robert G Cooper,UK-BILD Collaboration

DOI: https://doi.org/10.1016/j.clim.2024.110201

Abstract:Background: Autoantibodies are a hallmark feature of Connective Tissue Diseases (CTD). Their presence in patients with idiopathic interstitial lung disease (ILD) may suggest covert CTD. We aimed to determine the prevalence of CTD autoantibodies in patients diagnosed with idiopathic ILD. Methods: 499 patient sera were analysed: 251 idiopathic pulmonary fibrosis (IPF), 206 idiopathic non-specific interstitial pneumonia (iNSIP) and 42 cryptogenic organising pneumonia (COP). Autoantibody status was determined by immunoprecipitation. Results: 2.4% of IPF sera had a CTD-autoantibody compared to 10.2% of iNSIP and 7.3% of COP. 45% of autoantibodies were anti-synthetases. A novel autoantibody targeting an unknown 56 kDa protein was found in seven IPF patients (2.8%) and two NSIP (1%) patients. This was characterised as anti-annexin A11. Conclusion: Specific guidance on autoantibody testing and interpretation in patients with ILD could improve diagnostic accuracy. Further work is required to determine the clinical significance of anti-annexin A11.
Comments on the current status and future development of natural orifice transluminal endoscopic surgery

K. Fuchs

DOI: https://doi.org/10.1111/ans.12984

IF: 1.7

2015-04-01

ANZ Journal of Surgery

Abstract:Natural orifice transluminal endoscopic surgery (NOTES) has emerged in the early 2000 as a logical development of ideas originating from interventional endoscopists. The process was supported by gastrointestinal surgeons with the motivation to expand the possibilities of minimal access surgery. The US-based NOSCAR group, followed by the EuroNOTES group, established yearly summit workshops to exchange knowledge and promote research. After the initial hype of ideas and fantasies of performing intra-abdominal surgery via flexible endoscopes, followed by a more critical phase of reflection and after years of intensive work in many dedicated centres, the concept of NOTES has become a clinical reality. This has happened, despite the early disappointment of many, due to the complex problems and the technical limitations of NOTES procedures. The principle of minimal access surgery is the reduction of access size and access trauma aiming for a shorter patient recovery; improved post-operative well-being; better cosmesis; less postoperative restriction allowing the patient to return quickly back to full physical and psychological abilities, and possibly an improved long-term outcome. The latter is achieved by reduction in wound infections and less incisional hernias over time. The advantages of the concept of minimal access surgery over conventional open surgery have been clearly shown in the past decades. It is best to consider that NOTES is not a technique, but a concept. The concept being that NOTES can cause further reduction of access trauma by using a natural orifice as an access route to the intraabdominal cavity. Further minimizing access trauma at the abdominal or thoracic wall could possibly lead to less post-operative pain, improved and quicker recovery from surgery, less post-operative complications, less wound infection and less long-term problems such as hernias. Some authors comment that NOTES is ‘dead’ because the hype has not created a revolution as seen with laparoscopic surgery in the 1990s. This argument is premature considering laparoscopy has been around since the 1930s and operative laparoscopy did not start until the early 1980s, with the final breakthrough occurring in the early 1990s, with a remarkable rise in complications. Thus, it has been appropriate that there has been a careful assessment of the new ideas and techniques related to NOTES and even more careful introduction into clinical practice. After 5 years of experimental and clinical practice, clinical evaluation and evidence assessment reveals the infection issue is not a major concern and the frequency of infectious NOTES complications is low. The principle of hybrid techniques has overcome some of the limitations that inhibited the clinical breakthrough of NOTES techniques. In hybrid procedures, trans-abdominal trocars are used in limited numbers and limited size to facilitate, assist and/or enable the manoeuvres through the natural orifice via graspers for better retraction, exposure and/or delivery of rigid energy devices. Despite the fact that trans-abdominal instruments will limit the possible positive effects of NOTES, hybrid procedures usually increase patient safety by facilitating the use of experienced and safe laparoscopic techniques. The first comparative trials have been published demonstrating the possible advantage of NOTES-hybrid procedures over classic laparoscopic cholecystectomy specifically assessing the cosmetic result. Randomized trials are on the way. Using the trans-oesophageal route, one of the current and most promising NOTES procedures is Per-Oral Endoscopic Myotomy (POEM). Several clinical indications are being evaluated for the use of the POEM techniques such as achalasia, diffuse esophageal spasm, other spastic motility disorders and mediastinal exploration. With respect to achalasia, POEM is becoming an established therapeutic option compared with alternatives such as endoscopic dilation and laparoscopic oesophageal myotomy. The trans-anal/trans-colonic approaches were considered to be a problem because of the bacterial load of the colon and the potential for infection. Presently, trans-anal and trans-colonic hybrid-NOTES procedures are increasingly performed in Europe. Based on the long-term clinical experiences of trans-anal endoscopic mucosectomy and based on the conceptual modifications that were made in the past years for using the anastomotic site as a natural orifice into the abdominal cavity, trans-anal hybrid colon resections and trans-anal hybrid rectal resections are now the most promising development in NOTES today. In the past 24 months, there have been hundreds of trans-anal colon resections and trans-anal TME procedures performed in Europe. The safe performance of these NOTES procedures requires increased experience and mental work load compared with traditional minimal invasive surgery. As well, interventional endoscopy and advanced laparoscopy must be well established prior to involving NOTES techniques. In summary, NOTES and more frequently hybrid-NOTES techniques have emerged for all natural orifices. Interesting enough, different indications are used for different natural orifices. Each technique has been optimized for the purpose of finding a safe and realistic solution to perform the procedure according to the specific indication. Each approach has been established clinically with a good safety record so far. The most important result is the low complication rate that could be realized during the introduction of NOTES and associated techniques in clinical practice in contrast to the introduction of operative laparoscopy. EDITORIAL
[Dermatomyositis and Autoantibodies]

Manabu Fujimoto

DOI: https://doi.org/10.11477/mf.1416201015

Abstract:Recent studies have identified novel dermatomyositis-specific autoantibodies and revealed that disease-specific autoantibodies become positive at a high rate in this disease. Moreover, these autoantibodies have been demonstrated to show a strong correlation with distinct clinical manifestations and complications such as interstitial lung disease and malignancy. Thus, these autoantibodies are now recognized as useful tools to classify this varied disease into more homogeneous subsets. In this review, the clinical significance of five dermatomyositis-specific autoantibodies, anti-Mi-2, anti-MDA5, anti-TIF1, anti-NXP2, and anti-SAE, was described.
Disease-specific autoantibody production in the lungs and salivary glands of anti-synthetase syndrome

Masaru Takeshita,Katsuya Suzuki,Maho Nakazawa,Hirofumi Kamata,Makoto Ishii,Yoshitaka Oyamada,Hisaji Oshima,Satoshi Usuda,Kazuyuki Tsunoda,Tsutomu Takeuchi

DOI: https://doi.org/10.3389/fimmu.2024.1265792

IF: 7.3

2024-06-14

Frontiers in Immunology

Abstract:Interstitial lung disease is a common complication of anti-synthetase syndrome (ASS), and lymphocytic infiltration is often observed in the lesion. We have recently reported that disease-specific autoantibodies are produced by infiltrating lymphocytes in some autoimmune diseases. Here, we investigate the antigen specificity of B cells in the lung lesions of ASS patients. A total of 177 antibodies were produced from antibody-secreting cells in bronchoalveolar fluid (BALF) of three each of serum anti-Jo-1 and serum anti-EJ antibody–positive patients. Twelve to 30% and 50 to 62% of these antibodies were disease-specific autoantibodies, respectively. These autoantibodies recognized conformational epitopes of the whole self-antigen and had affinity maturations, indicating that self-antigens themselves are the target of humoral immunity. In addition, 100 antibodies were produced from two salivary gland tissues, obtained by chance, of ASS patients. Salivary glands are not generally recognized as lesions of ASS, but unexpectedly, ASS-related autoantibody production was also observed similar to that of BALF. Immunostaining confirmed the presence of ASS-related autoantibody-producing cells in salivary glands. Our results suggest that disease-specific autoantibody production at lesion sites is a common pathogenesis of autoimmune diseases, and that tissue-specific production of autoantibodies can provide insights regarding the distribution of organ manifestations in autoimmune diseases.

immunology
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease in Connective Tissue Diseases.

Si Wu,Xiaojun Tang,Liping Wu,Liang-Jing Lu,Xuebing Feng

DOI: https://doi.org/10.1136/annrheumdis-2019-216372

IF: 27.973

2019-01-01

Annals of the Rheumatic Diseases

Abstract:We read with great interest the article by Sabbagh et al demonstrating that anti-Ro52 autoantibodies were connected with the development of interstitial lung disease (ILD) in patients with juvenile myositis.1 Anti-Ro52 has been found in a variety of connective tissue diseases (CTDs) and drawn considerable attention from rheumatologists in recent years. Besides myositis, these autoantibodies have also been reported to be related to ILD in several other CTDs, but with great discrepancy across the studies.2 In addition, it remains unclear how the incidence of ILD differs in the presence of anti-Ro52 alone or in combination with anti-Ro60 (Sjogren's syndrome related antigen A), one of the most associated antibodies that may determine anti-Ro52 …
Brief Report: Anti-Eukaryotic Initiation Factor 2b Autoantibodies Are Associated with Interstitial Lung Disease in Patients with Systemic Sclerosis

Zoe E. Betteridge,Felix Woodhead,Hui Lu,Gavin Shaddick,Christopher C. Bunn,Christopher P. Denton,David J. Abraham,Roland M. du Bois,Mervyn Lewis,Athol U. Wells,Neil J. McHugh

DOI: https://doi.org/10.1002/art.39755

2016-01-01

Arthritis & Rheumatology

Abstract:ObjectiveTo investigate novel systemic sclerosis (SSc) autoantibodies in autoantibody‐negative patients and establish clinical associations.MethodsSerum samples and clinical data for 548 patients with SSc were collected. Routine serologic techniques were used to test the serum samples for known SSc autoantibodies, and samples with negative results were further investigated by radiolabeled‐protein immunoprecipitation assay. Sera that immunoprecipitated a novel 30‐kd band were analyzed by indirect immunofluorescence and immunoprecipitation, using depleted cell extracts to establish a common reactivity. Mass spectrometry was performed to identify the novel autoantigen, and the results were confirmed using commercial antibodies. Sera from 426 patients with other forms of connective tissue disease, 103 with rheumatoid arthritis, 114 with idiopathic interstitial lung disease (ILD), and 150 healthy subjects were serotyped as controls.ResultsA novel autoantigen with a molecular weight of ∼30 kd was recognized by 7 sera from patients with SSc, 6 of whom had ILD, and by no controls. Six of the patients had diffuse cutaneous involvement, and 4 had overlap features with other autoimmune diseases. Immunodepletion experiments indicated that all samples targeted the same autoantigen, and mass spectrometry identified the novel autoantigen as eukaryotic initiation factor 2B (eIF2B).ConclusionWe report the identification of a novel autoantibody (anti‐eIF2B) in a small number of patients with SSc (∼1%); this autoantibody is closely associated with diffuse cutaneous manifestations and the presence of ILD.
Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders

Masataka Kuwana,Albert Gil-Vila,Albert Selva-O’Callaghan

DOI: https://doi.org/10.1177/1759720X211032457

2021-07-28

Therapeutic Advances in Musculoskeletal Disease

Abstract:Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren's syndrome or the mixed connective tissue disease, are also discussed.

rheumatology
Functional analysis of Drosophila melanogaster BRCA2 in DNA repair.

R. Brough,Debbie Wei,Sophie Leulier,C. Lord,Y. Rong,A. Ashworth

DOI: https://doi.org/10.1016/J.DNAREP.2007.07.013

IF: 4.354

DNA Repair

Abstract:
Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features

Mingshan Xue,Chuanxu Cai,Yifeng Zeng,Yifan Xu,Huai Chen,Haisheng Hu,Luqian Zhou,Baoqing Sun

DOI: https://doi.org/10.1097/md.0000000000024260

IF: 1.6

2021-01-29

Medicine

Abstract:Interstitial pneumonia with autoimmune features (IPAF) is a special subtype of interstitial lung disease that has received worldwide attention. Krebs von den Lungen-6 (KL-6) and surfactant protein-A (SP-A) can be used as an important biomarker of interstitial lung disease, but its exact relationship with IPAF is poorly understood.

medicine, general & internal
Singular sets of separately analytic functions

Zbigniew Blocki

DOI: https://doi.org/10.4064/AP-56-2-219-225

Abstract:In this paper we complete the characterization of singular sets of separately analytic functions. In the case of functions of two variables it was earlier done by J. Saint Raymond and J. Siciak. -1.Introduction. If Ω is an open subset of Rn1×· · ·×Rns , then we say that a function f : Ω −→ C is p−separately analytic (1 ≤ p < s), if for every x = x01, . . . , xs ) ∈ Ω and for every sequence 1 ≤ i1 < · · · < ip ≤ s the function ( xi1 , . . . , xip ) −→ f x01, . . . , xi1 , . . . , xip , . . . , xs ) is analytic in a neighbourhood of ( x0i1 , . . . , x 0 ip ) . For a p−separately analyitc function f in Ω let A (f) := {x ∈ Ω : f is analytic in a neighbourhood of x} denote its set of analycity, and S (f) := Ω \A(f) its singular set. If X and Y are any sets, S ⊂ X×Y and (x0, y0) ∈ X×Y , then we denote S (x0, •) := { y ∈ Y : (x0, y) ∈ S}, S (•, y0) := {x ∈ X : (x, y0) ∈ S}. The following theorems characterize singular sets of separately analytic functions: Theorem A. If f is p−separately analytic in Ω, then for every sequence 1 ≤ j1 < · · · < jq ≤ s, where q := s − p, the projection of S (f) on Rj1 × · · · ×Rnjq is pluripolar (in Cj1 × · · · ×Cnjq ). Theorem B. Let S be a closed subset of Ω such that for every sequence 1 ≤ j1 < · · · < jq ≤ s, where q := s−p, the projection of S on Rj1 ×· · ·×Rnjq is pluripolar. Then there exists p−separately anlytic function f in Ω such that S = S (f). Theorem C. Let f be a p−separately analytic in Ω. If 1 ≤ k < s, then for quasi almost all x ∈ R1 ×· · ·×Rnk (that is for x ∈ R1 ×· · ·×Rnk \P , where P is pluripolar) S (f (x, •)) = S (f) (x, •). Theorems A and B in case s = 2, p = n1 = n2 = 1 were proved by Saint Raymond [2]. This result was generelized by Siciak [5], who proved theorem A for p ≥ s/2 and theorem B. The aim of this paper is to give a proof of theorem C and, as a trivial consequence, we get theorem A. 0.Preliminaries. We need the following two theorems: Siciak’s theorem ([3]; see also [4], theorem 9.7). Let for j = 1, . . . , s Dj = D j × · · · × Dj j , D j open sets in C, symmetric with respect to xt-axis (t = 1, . . . , nj), Kj = K j ×· · ·×Kj j , K j closed intervals in D j∩R. Let f be a separately holomorphic function in X := s ⋃ j=1 K1 × · · · ×Dj × · · · ×Ks
Enantioselective synthesis of optically active 3,3-diarylpropanoates by conjugate hydrosilylation with chiral Rh-bis(oxazolinyl)phenyl catalysts.

K. Itoh,Ayae Tsuruta,Jun-Ichi Ito,Yoshihiko Yamamoto,H. Nishiyama

DOI: https://doi.org/10.1021/jo302357b

2012-11-16

Abstract:Conjugate hydrosilylation of 3,3-diarylacrylate derivatives catalyzed by chiral rhodium-bis(oxazolinyl)phenyl complexes (1 mol %) at 60 °C for 2 h was investigated to prepare optically active 3,3-diarylpropanoate derivatives in high yields up to 99% yield and high enantioselectivities up to 99%.
Autoantibodies to nuclear valosin-containing protein-like protein: systemic sclerosis-specific antibodies revealed by in vitro human proteome

Kazuki M Matsuda,Hirohito Kotani,Kei Yamaguchi,Chihiro Ono,Taishi Okumura,Koji Ogawa,Ayako Miya,Ayaka Sato,Rikako Uchino,Murakami Yumi,Hiroshi Matsunaka,Masanori Kono,Yuta Norimatsu,Teruyoshi Hisamoto,Ruriko Kawanabe,Ai Kuzumi,Takemichi Fukasawa,Asako Yoshizaki-Ogawa,Tomohisa Okamura,Hirofumi Shoda,Keishi Fujio,Takashi Matsushita,Naoki Goshima,Shinichi Sato,Ayumi Yoshizaki

DOI: https://doi.org/10.1093/rheumatology/keae063

2024-01-30

Rheumatology

Abstract:Abstract Objectives To identify and characterize undescribed systemic sclerosis (SSc)-specific autoantibodies targeting nucleolar antigens and to assess their clinical significance. Methods We conducted proteome-wide autoantibody screening (PWAS) against serum samples from SSc patients with nucleolar patterned anti-nuclear antibodies (NUC-ANAs) of specific antibodies (Abs) unknown, utilizing wet protein arrays fabricated from in vitro human proteome. Controls included SSc patients with already-known SSc-specific autoantibodies, patients with other connective tissue diseases and healthy subjects. The selection of nucleolar antigens was performed by database search in the Human Protein Atlas. The presence of autoantibodies was certified by immunoblots and immunoprecipitations. Indirect immunofluorescence assays on HEp-2 cells were also conducted. Clinical assessment was conducted by retrospective review of electronic medical records. Results PWAS identified three candidate autoantibodies, including anti-nuclear valosin-containing protein-like (NVL) Ab. Additional measurements in disease controls revealed that only anti-NVL Abs are exclusively detected in SSc. Detection of anti-NVL Abs was reproduced by conventional assays such as immunoblotting and immunoprecipitation. Indirect immunofluorescence assays demonstrated homogeneous nucleolar patterns. Anti-NVL Ab-positive cases were characterized by significantly low prevalence of diffuse skin sclerosis and interstitial lung disease, compared with SSc cases with NUC-ANAs other than anti-NVL Abs, such as anti-U3-RNP and anti-Th/To Abs. Conclusion Anti-NVL Ab is an SSc-specific autoantibody associated with a unique combination of clinical features, including limited skin sclerosis and lack of lung involvement.

rheumatology
Nitroblue tetrazolium test.

C. McCall,M. Cooper,L. Dechatelet

DOI: https://doi.org/10.1016/S0022-3476(71)80087-2

IF: 2.99

1971-07-01

Jornal de Pediatria

Abstract:
Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis

Hanna Graßhoff,Konstantinos Fourlakis,Sara Comdühr,Gabriela Riemekasten

DOI: https://doi.org/10.3390/biomedicines10092150

IF: 4.757

2022-09-02

Biomedicines

Abstract:Systemic sclerosis (SSc) is a rare connective tissue disorder characterized by immune dysregulation evoking the pathophysiological triad of inflammation, fibrosis and vasculopathy. In SSc, several alterations in the B-cell compartment have been described, leading to polyclonal B-cell hyperreactivity, hypergammaglobulinemia and autoantibody production. Autoreactive B cells and autoantibodies promote and maintain pathologic mechanisms. In addition, autoantibodies in SSc are important biomarkers for predicting clinical phenotype and disease progression. Autoreactive B cells and autoantibodies represent potentially promising targets for therapeutic approaches including B-cell-targeting therapies, as well as strategies for unselective and selective removal of autoantibodies. In this review, we present mechanisms of the innate immune system leading to the generation of autoantibodies, alterations of the B-cell compartment in SSc, autoantibodies as biomarkers and autoantibody-mediated pathologies in SSc as well as potential therapeutic approaches to target these.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases

Wieke M. van Oostveen,Tom W. J. Huizinga,Cynthia M. Fehres

DOI: https://doi.org/10.1111/imr.13390

2024-09-11

Immunological Reviews

Abstract:Summary Systemic sclerosis (SSc) is a severe autoimmune disease characterized by vasculopathy, fibrosis, and dysregulated immunity, with hallmark autoantibodies targeting nuclear antigens such as centromere protein (ACA) and topoisomerase I (ATA). These autoantibodies are highly prevalent and disease‐specific, rarely coexisting, thus serving as crucial biomarkers for SSc diagnosis. Despite their diagnostic value, their roles in SSc pathogenesis remain unclear. This review summarizes current literature on ACA and ATA in SSc, comparing them to autoantibodies in other rheumatic diseases to elucidate their potential pathogenic roles. Similarities are drawn with anti‐citrullinated protein antibodies (ACPA) in rheumatoid arthritis, particularly regarding disease specificity and minimal pathogenic impact of antigen binding. In addition, differences between ANA and ACPA in therapeutic responses and Fab glycosylation patterns are reviewed. While ACA and ATA are valuable for disease stratification and monitoring activity, understanding their origins and the associated B cell responses is critical for advancing therapeutic strategies for SSc.

immunology
[Significance of Anti-Tubulin-α-1c Autoantibody in Systemic Sclerosis].

J Zhao,F Sun,Y Li,X Z Zhao,D Xu,Y N Li,Y H Li,X L Sun

DOI: https://doi.org/10.19723/j.issn.1671-167x.2020.06.004

2020-01-01

Abstract:OBJECTIVE:To detect the serum level of a novel autoantibody, anti-tubulin-α-1C, in patients with systemic sclerosis (SSc) and to investigate its clinical significance.METHODS:Anti-tubulin-α-1C antibody levels were determined by enzyme-linked immunosorbent assay (ELISA) in 62 patients with SSc, 38 systemic lupus erythematosus (SLE), 24 primary Sjögren's syndrome (pSS) patients, and 30 healthy controls (HCs). Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), immunoglobulin A(IgA), immunoglobulin M (IgM), immunoglobulin G (IgG), C3, C4, rheumatoid factor (RF), antinuclear antibody(ANA), anti-centromere antibodies(ACA), anticardiolipin (aCL), anti-dsDNA antibody, anti-Sm antibody, anti-RNP antibody, anti-Scl-70 antibody, anti-Ro52 antibody, anti-SSA antibody, anti-SSB antibody, centromere protein A(CENP-A), centromere protein B (CENP-B) were measured by standard laboratory techniques. Raynaud's phenomenon and modified Rodnan skin score(MRSS) were recorded to evaluate the disease status of SSc. Independent sample t test, Chi square test, Mann-Whitney U test, Spearman rank correlation were used for statistical analyses.RESULTS:The serum anti-tubulin-α-1C antibody concentration in SSc group was 81.24±34.38, the serum anti-tubulin-α-1C antibody concentration in SLE group was 87.84±38.52, the serum anti-tubulin-α-1C antibody concentration in pSS group was 59.79±25.24, and the serum anti-tubulin-α-1C antibody concentration in healthy group was 39.37±18.7. Multivariate analysis revealed that anti-tubulin-α-1C antibody levels were significantly increased in the SSc and SLE patients. The expression level of anti-tubulin-α-1C antibody in SSc was higher compared with the pSS group and the health control group (P < 0.01). Further analysis demonstrated that the elevated anti-tubulin-α-1C antibody were correlated with the SSc inflammation and disease activity markers ESR(r=0.313, P=0.019), The levels of anti-tubulin-α-1C antibody were also significantly correlated with MRSS(r=0.636, P < 0.01). The best cut-off value for the diagnose of SSc was 76.77 as mean+2SD value. The proportion of Raynaud's phenomenon was higher in the group of anti-tubulin-α-1C autoantibody-postive SSc patients than that in anti-tubulin-α-1C autoantibody negative group(71.4% vs. 37.5%, P=0.039). The proportions of anti-Scl-70 antibody, anti-CENP antibody and anti-cardiolipin antibody were higher in the group of anti-tubulin-α-1C autoantibody-postive SSc patients than in the anti-tubulin-α-1C autoantibody negative group (37.9% vs. 15.2%, 34.5% vs. 12.1%, 13.8 vs. 0, respectively, all P < 0.05).CONCLUSION:Based on this explorative stu-dy, the level of anti-tubulin-α-1C antibody increased in the serum of the patients with SSc. There were correlations between anti-tubulin-α-1C autoantibody and clinical and laboratory indicators of the SSc patients. It may become a novel biomarker indicative of active SSc and could be applied in future clinical practice.
Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

Adelle S. Jee,Stephen Adelstein,Jane Bleasel,Gregory J. Keir,MaiAnh Nguyen,Joanne Sahhar,Peter Youssef,Tamera J. Corte,Adelle Jee,Gregory Keir,Tamera Corte

DOI: https://doi.org/10.3390/jcm6050051

IF: 3.9

2017-05-04

Journal of Clinical Medicine

Abstract:The diagnosis of interstitial lung disease (ILD) requires meticulous evaluation for an underlying connective tissue disease (CTD), with major implications for prognosis and management. CTD associated ILD (CTD-ILD) occurs most commonly in the context of an established CTD, but can be the first and/or only manifestation of an occult CTD or occur in patients who have features suggestive of an autoimmune process, but not meeting diagnostic criteria for a defined CTD-recently defined as "interstitial pneumonia with autoimmune features" (IPAF). The detection of specific autoantibodies serves a critical role in the diagnosis of CTD-ILD, but there remains a lack of data to guide clinical practice including which autoantibodies should be tested on initial assessment and when or in whom serial testing should be performed. The implications of detecting autoantibodies in patients with IPAF on disease behaviour and management remain unknown. The evaluation of CTD-ILD is challenging due to the heterogeneity of presentations and types of CTD and ILD that may be encountered, and thus it is imperative that immunologic tests are interpreted in conjunction with a detailed rheumatologic history and examination and multidisciplinary collaboration between respiratory physicians, rheumatologists, immunologists, radiologists and pathologists.

medicine, general & internal
Presence Of Anti-Eukaryotic Initiation Factor-2b, Anti-Ruvbl1/2 And Anti-Synthetase Antibodies In Patients With Anti-Nuclear Antibody Negative Systemic Sclerosis

John D Pauling,Gloria Salazar,Hui Lu,Zoe E Betteridge,Shervin Assassi,Maureen D Mayes,Neil J McHugh

DOI: https://doi.org/10.1093/rheumatology/kex458

2018-01-01

Rheumatology

Abstract:Objectives. Autoantibodies targeting ubiquitously expressed nuclear antigens can be identified in most patients with SSc. Cytoplasmic autoantibodies (in otherwise ANA-negative sera) targeting eukaryotic initiation factor-2B (anti-eIF2B) have recently been identified in SSc with clinical associations to dcSSc disease and interstitial lung disease (ILD), although the majority of samples originated from a tertiary SSc-ILD centre. We investigated the prevalence and clinical associations of recently described SSc-specific (including anti-eIF2B) and other cytoplasmic autoantibodies in ANA-negative sera obtained from a large representative SSc cohort.Methods. ANA-negative sera from the Scleroderma Family Registry and DNA Repository underwent indirect immunofluorescence, radiolabelled protein immunoprecipitation (+/- immunodepletion) to identify anti-eIF2B and other CTD-related autoantibodies. The clinical phenotype of positive samples was evaluated.Results. Immunoprecipitation was performed on 128 ANA-negative samples (obtained from 3249 SSc patients). Anti-eIF2B antibodies were present in nine patients (7%), the majority of whom had dcSSc (8/9). SSc-ILD was present in all anti-eIF2B patients for whom chest imaging was available (7/9). Anti-synthetase autoantibodies (targeting PL12, PL7, OJ and Zo) were identified in seven patients (5.5%), all of whom fulfilled the 2013 ACR/EULAR classification criteria for SSc and had evidence of SSc-ILD where relevant outcomes were available for evaluation. Anti-RuvBL1/2 antibodies were identified in two patients with SSc-overlap syndromes.Conclusion. Anti-eIF2B antibodies are cytoplasmic SSc-specific autoantibodies with strong clinical associations with dcSSc and SSc-ILD found in ANA-negative sera. Anti-synthetase autoantibodies, and other recently discovered SSc-specific antibodies such as anti-RuvBL1/2, can also be identified in ANA-negative SSc.

Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease.

A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung disease

Comments on the current status and future development of natural orifice transluminal endoscopic surgery

[Dermatomyositis and Autoantibodies]

Disease-specific autoantibody production in the lungs and salivary glands of anti-synthetase syndrome

Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease in Connective Tissue Diseases.

Brief Report: Anti-Eukaryotic Initiation Factor 2b Autoantibodies Are Associated with Interstitial Lung Disease in Patients with Systemic Sclerosis

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders

Functional analysis of Drosophila melanogaster BRCA2 in DNA repair.

Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features

Singular sets of separately analytic functions

Enantioselective synthesis of optically active 3,3-diarylpropanoates by conjugate hydrosilylation with chiral Rh-bis(oxazolinyl)phenyl catalysts.

Autoantibodies to nuclear valosin-containing protein-like protein: systemic sclerosis-specific antibodies revealed by in vitro human proteome

Nitroblue tetrazolium test.

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis

Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases

[Significance of Anti-Tubulin-α-1c Autoantibody in Systemic Sclerosis].

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

Presence Of Anti-Eukaryotic Initiation Factor-2b, Anti-Ruvbl1/2 And Anti-Synthetase Antibodies In Patients With Anti-Nuclear Antibody Negative Systemic Sclerosis